LEP and asthma: Collectively, these findings suggest that a short-term course of high-dose ICSs in adults with mild asthma does not induce clinically or statistically significant changes in appetite, dietary intake, serum leptin levels, or body weight, supporting the metabolic safety profile of short-term high-dose ICS therapy in this patient population.